Welcome to our dedicated page for Radius Recycling news (Ticker: RDUS), a resource for investors and traders seeking the latest updates and insights on Radius Recycling stock.
Radius Recycling, Inc. (NASDAQ: RDUS), formerly known as Schnitzer Steel Industries, Inc., stands as a prominent figure in North America's recycling and steel manufacturing industry. Established in 1906 in Portland, Oregon, the company has evolved from a small, one-man scrap metal operation into a major player in the market, boasting a diversified and vertically integrated business model.
Radius Recycling specializes in the recycling of ferrous and nonferrous metals, including end-of-life vehicles, and the manufacture of finished steel products. Their operational network comprises 54 metals recycling facilities, 50 self-service auto parts stores, and an electric arc furnace steel mill. This extensive infrastructure enables Radius to meet global demand efficiently.
Key Business Units:
- Metals Recycling Business: Processes a substantial quantity of recycled ferrous and nonferrous metals, significantly contributing to environmental sustainability and resource conservation.
- Auto Parts Business: Operates 50 retail stores selling serviceable parts from salvaged vehicles, receiving over 4 million annual visits from retail customers.
- Steel Manufacturing Business: Produces a variety of finished steel products, including rebar and wire rod, using eco-friendly electric arc furnace technology.
Despite the challenges posed by tight supply flows and adverse weather conditions impacting sales volumes, Radius Recycling has demonstrated resilience and adaptability. Recent productivity initiatives aim to reduce selling, general, and administrative expenses by 10%, alongside increasing production efficiencies, expected to yield $40 million in annual benefits.
Recent Financial Highlights:
- Revenue: Achieved $2.5 billion in fiscal 2014, reflecting robust market presence and operational efficiency.
- Global Reach: Positions in 25 states, Puerto Rico, and Western Canada, with deep-water export facilities expanding its market access.
- Strategic Initiatives: Focused on enhancing nonferrous production and expanding recycling services, positioning the company favorably against market headwinds.
Under the leadership of Tamara Lundgren, Chairman and CEO, Radius Recycling remains focused on cost control, operational efficiency, and strategic growth. The company's commitment to sustainability and low-carbon technologies aligns with global decarbonization trends, positioning Radius to capitalize on future market opportunities.
Partnerships and Projects: Radius continues to invest in advanced metal recovery technologies and expand its recycling platform, supporting its mission of promoting environmental sustainability and efficient resource use.
The company will report its financial results for the second quarter of fiscal 2024 on April 4, 2024, with a webcast conference call hosted by Tamara Lundgren and Stefano Gaggini, Senior Vice President and CFO, to discuss the results.
Radius Health, Inc. (NASDAQ: RDUS) will release its fourth quarter and full year 2021 financial results on February 24, 2022. Following the announcement, the company will host a conference call at 8:30 a.m. ET to discuss results and provide updates. Interested parties can join via dial-in or webcast. A replay of the call will be available starting on February 24 at 11:30 a.m. ET through March 3. Radius Health focuses on biopharmaceuticals in bone health, neuroscience, and oncology.
Radius Health, Inc. (NASDAQ: RDUS) has restructured its operations following the completion of three pivotal clinical trials in 2021. The restructuring entailed a reduction of approximately 20% in non-sales headcount, targeting roles supporting the abaloparatide clinical and regulatory activities. While the ATOM and EMERALD studies reported positive outcomes, the wearABLe study failed to meet its primary endpoint. The company is set to report its Q4 and FY 2021 results along with its 2022 outlook on February 24, 2022.
Radius Health announced that the FDA has approved the removal of the boxed warning regarding osteosarcoma risks from the label of TYMLOS, effective December 22, 2021. This decision follows a comprehensive review of long-term post-marketing data. The update aims to provide healthcare professionals and patients with critical information for better treatment decisions. Radius remains focused on exploring further label adjustments with ongoing discussions with the FDA.
The EMERALD trial results revealed that elacestrant significantly improves progression-free survival (PFS) in patients with ER+/HER2- advanced breast cancer. As the first oral selective estrogen receptor degrader (SERD), elacestrant reduced the risk of progression or death by 30% in the overall population and 45% in patients with estrogen receptor mutations (mESR1). The PFS rate at 12 months was 22.32% for elacestrant compared to 9.42% with standard care. Both Menarini and Radius Health are optimistic about the implications of these findings for regulatory submissions in 2022.
BOSTON, Dec. 08, 2021 - Radius Health announced a conference call on December 8, 2021, at 4:00 p.m. ET. The call will discuss topline results from the wearABLe Phase 3 trial and review data from the EMERALD Phase 3 trial presented at the San Antonio Breast Cancer Symposium. Interested parties can join via a domestic dial-in number at 1 (866) 323-7965 or internationally at 1 (346) 406-0961, using conference ID 7691981. A replay will be available later on the same day and archived for 90 days on the Company's website.
Radius Health, Inc. (NASDAQ: RDUS) announced the topline results of its phase 3 wearABLe study, comparing the abaloparatide transdermal system (abalo-TDS) with TYMLOS (abaloparatide subcutaneous injection) in postmenopausal women with osteoporosis. The study did not meet its primary endpoint of non-inferiority, showing a lumbar spine BMD increase of 7.1% for abalo-TDS versus 10.9% for TYMLOS. Both treatments were well tolerated, with no significant safety issues found. The data will inform future plans for abalo-TDS development.
BOSTON, Nov. 11, 2021 – Radius Health, Inc. (NASDAQ: RDUS) will participate in the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 8:40 a.m. ET, featuring a fireside chat and investor meetings. A live webcast of the chat will be accessible via the Company’s website, with a 90-day replay available post-event. Radius focuses on unmet medical needs in bone health, orphan diseases, and oncology, with its lead product TYMLOS® FDA-approved for postmenopausal osteoporosis. The pipeline includes multiple investigational drugs for various conditions.
Radius Health reported Q3 2021 net revenue of $57 million, a 13% increase from Q3 2020. However, total company revenue dropped by 27% year-over-year due to a lack of license revenue in the current quarter. Adjusted EBITDA was negative $11 million compared to a positive $9 million in the previous year. The company plans to lower its FY 2021 TYMLOS revenue forecast to $210-$220 million and adjusted EBITDA to a loss of $5-$15 million. Notably, the EMERALD study showed positive results for elacestrant, with regulatory submissions planned for 2022.
Radius Health, Inc. (NASDAQ: RDUS) will release its third quarter financial results on November 8, 2021, followed by a conference call at 8:30 a.m. ET. Investors can join via a domestic dial-in at 1 (855) 404-2458 or internationally at 1 (430) 775-1272, using conference ID 9322858. A replay will be available the same day at 11:30 a.m. ET. Radius focuses on unmet medical needs in bone health and oncology, with its lead product, TYMLOS®, approved for high-risk postmenopausal women with osteoporosis.
FAQ
What is the current stock price of Radius Recycling (RDUS)?
What is the market cap of Radius Recycling (RDUS)?
What is Radius Recycling, Inc.?
What does Radius Recycling do?
Where is Radius Recycling headquartered?
What are the key business units of Radius Recycling?
How has Radius Recycling performed financially?
What are the latest financial results for Radius Recycling?
What are Radius Recycling's strategic initiatives?
Who is the CEO of Radius Recycling?
How does Radius Recycling contribute to sustainability?
Where can I find more information about Radius Recycling?
